SCHEMBL6743269

SCHEMBL6743269

CCOC(=O)c1ccc(CCc2ccnc(N)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAOA P21397 1/20 0.50
CDC7 O00311 1/20 0.46
DBF4 Q9UBU7 1/20 0.46
HTT P42858 2/20 0.45
NAMPT P43490 2/20 0.44
KMT2A Q03164 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ESR1 P03372 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
ESR2 Q92731 1/20 0.44
CA14 Q9ULX7 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260948 0.81 NPC1 (0.53) LMNACYP1A2CYP3A4MAOAHTT
Hydrochloric Acid SCHEMBL6744451 0.80 EP300 (0.41) ROCK1
SCHEMBL12199135 0.78 CA1 (0.68) LMNACYP1A2CYP3A4MAOAHTT
SCHEMBL8083373 0.78 SUCNR1 (0.45) LMNACYP1A2NAMPTCA12CA1
SCHEMBL7491665 0.77 NOS1 (0.54) LMNACYP1A2CYP3A4MAOAHTT
SCHEMBL12228832 0.73 CYP1A2 (0.59) LMNACYP1A2CYP3A4MAOACDC7
SCHEMBL10765170 0.73 CYP4A11 (0.62) LMNACYP1A2CYP3A4MAOAHTT
SCHEMBL5734417 0.73 LMNA (0.68) LMNACYP1A2CYP3A4MAOAHTT
SCHEMBL571227 0.72 CA1 (0.63) LMNACYP1A2CYP3A4MAOAHTT
SCHEMBL16664040 0.71 CA12 (0.58) LMNACYP1A2CYP3A4MAOAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693101-B2 ALKANOIC ACID DERIVATIVE; INTEGRIN RECEPTOR ANTAGONIST MERCK & CO., INC. 2004-02-17 US disclosed
US-20010053853-A1 Alpha V integrin receptor antagonists MERCK & CO., INC. 2001-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053853-A1 Alpha V integrin receptor antagonists ITGAV, ADGRE5, ITGA5 LMNA 3379/4885CYP1A2 4151/4885CYP3A4 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.